Qiagen, Inovio expand collaboration to develop NGS CDx

Create PDF

VGX-3100 is Inovio’s late-stage DNA immunotherapy candidate. It is currently in two phase three trials (REVEAL 1 and REVEAL 2), with the potential to become the first nonsurgical treatment for advanced precancerous cervical lesions associated with HPV-16 and HPV-18.